Truist Financial analyst Asthika Goonewardene maintained a Buy rating on Genmab (GMAB – Research Report) today. The company’s shares closed ...

In a report released today, Vikram Purohit from Morgan Stanley maintained a Hold rating on Genmab (GMAB – Research Report), with a price target ...

We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against the other ...

Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an ...

Fintel reports that on March 11, 2025, William Blair upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market Perform ...

We recently compiled a list of the 10 Cash-Rich Undervalued Stocks To Invest In. In this article, we are going to take a look ...

Equities research analysts at William Blair issued their FY2029 earnings per share (EPS) estimates for shares of Genmab A/S ...

Assetmark Inc. lowered its position in Genmab A/S (NASDAQ:GMAB – Free Report) by 78.1% during the fourth quarter, Holdings ...

In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against other best growth stocks to invest in according to analysts. Companies experiencing above-average ...

In trading on Friday, shares of Genmab A/S (Symbol: GMAB) crossed above their 200 day moving average of $24.14, changing hands as high as $24.32 per share. Genmab A/S shares are currently trading ...

In this article, we are going to take a look at where Genmab A/S (NASDAQ:GMAB) stands against the other cash-rich undervalued stocks. Currently, big tech and high-growth stocks dominate the stock ...